Bioremediation of perfluorochemicals: current state and the way forward

First Clarification of the Mechanism of Action of the Apple Glycosyltransferase MdUGT91AJ2 Involved in the Detoxification Metabolism of the Triketone Herbicide Sulcotrione

Sulcotrione is a member of triketone herbicides, a class of HPPD (4-hydroxyphenylpyruvate dioxygenase) inhibitors with broad-spectrum herbicidal activity. Modifications of glycosylation mediated by glycosyltransferases (GT) are involved in plant detoxification. In this study, we analyzed chip data published online and found that eight glycosyltransferases from group A of the apple glycosyltransferase family 1 may be involved in the metabolic mechanism of detoxification of triketone herbicides. To verify this prediction, we induced apple seedlings with six types of triketone herbicides, and then detected the expression levels of eight glycosyltransferase genes through real-time PCR. We found that triketone herbicides induced up-regulation of eight glycosyltransferase genes to varying degrees, with MdUGT91AJ2 being the most significantly up-regulated by sulcotrione-induced glycosyltransferase gene expression. Then, through in vitro enzymatic reactions and HPLC identification of glycoside substrates, it was found that the glycosyltransferase MdUGT91AJ2 had the highest specific enzyme activity against the triketone herbicide sulcotrione. Furthermore, the in vivo mechanism of the glycosyltransferase MdUGT91AJ2 in the detoxification metabolism of sulcotrione was further validated by overexpressing the strain in the plant. HPLC analysis showed that the content of sulcotrione glycosides in the overexpressing strain of MdUGT91AJ2 was significantly higher than that in the wild type. This result indicated that the apple glycosyltransferase MdUGT91AJ2 can still glycosylate and modify sulfotrione in plants, and participate in its detoxification metabolism. In summary, this study identified for the first time a novel apple glycosyltransferase MdUGT91AJ2 and elucidated its mechanism of action in the detoxification and metabolism of the triketone herbicide sulfotriene.

The EU's Per- and Polyfluoroalkyl Substances (PFAS) Ban: A Case of Policy over Science

The proposal by the European Chemicals Agency (ECHA) to ban over 12,000 per- and polyfluoroalkyl substances (PFAS) has sparked a debate about potential consequences for the economy, industry, and the environment. Although some PFAS are known to be harmful, a blanket ban may lead to significant problems in attempting to replace PFAS-based materials for environmental transition, as well as in medical devices and everyday products. Alternative materials may potentially be less safe, as a rush to replace PFAS would reduce the time needed for toxicological analyses. Studies have shown that PFAS exhibit a diverse range of mechanisms of action, biopersistence, and bioaccumulation potential, and should thus not be treated as a single group. This is particularly true for the class of fluoropolymers. A targeted approach that considers the specific risks and benefits of each chemical may be more effective. Moreover, the proposed ban may also have unintended consequences for the environment as PFAS use is also associated with benefits such as reducing greenhouse-gas emissions and improving energy efficiency. Policymakers must carefully weigh up the potential consequences before making a final decision on the ban.

The application of bioremediation in wastewater treatment plants for microplastics removal: a practical perspective

Wastewater treatment plants (WWTPs) play the role of intercepting microplastics in the environment and provide a platform for bioremediation to remove microplastics. Despite, this opportunity has not been adequately studied. This paper shows the potential ways microplastics-targeted bioremediation could be incorporated into wastewater treatment through the review of relevant literature on bioaugmentation of water treatment processes for pollutants removal. Having reviewed more than 90 papers in this area, it highlights that bioremediation in WWTPs can be employed through bioaugmentation of secondary biological treatment systems, particularly the aerobic conventional activated sludge, sequencing batch reactor, membrane bioreactor and rotating biological contactor. The efficiency of microplastics removal, however, is influenced by the types and forms of microorganisms used, the polymer types and the incubation time (100% for polycaprolactone with Streptomyces thermoviolaceus and 0.76% for low-density polyethylene with Acinetobacter iwoffii). Bioaugmentation of anaerobic system, though possible, is constrained by comparatively less anaerobic microplastics-degrading microorganisms identified. In tertiary system, bioremediation through biological activated carbon and biological aerated filter can be accomplished and enzymatic membrane reactor can be added to the system for deployment of biocatalysts. During sludge treatment, bioaugmentation and addition of enzymes to composting and anaerobic digestion are potential ways to enhance microplastics breakdown. Limitations of bioremediation in wastewater treatment include longer degradation time of microplastics, incomplete biodegradation, variable efficiency, specific microbial activities and uncertainty in colonization. This paper provides important insight into the practical applications of bioremediation in wastewater treatment for microplastics removal.

The potential of microbubbles as a cancer eradication theranostic agent

Microbubbles are a new kind of delivery system that may be used to treat a variety of illnesses, including cancer. Microbubble is a non-invasive technology that uses microscopic gas-filled colloidal particle bubbles with a size range of less than 100 micrometres. This unique carrier has been used in a variety of applications in the last decade, ranging from basic targeting to ultrasound-mediated drug delivery. The oxygen in the microbubble lasts longer in the water. The drug release mechanism is highly regulated, since it releases the medication only in the appropriate areas, increasing the local impact while reducing drug toxicity. This carrier is exceptional in cancer medication delivery because of its sustained stability, encapsulation efficiency, and drug targeting. In this paper, we provide a comprehensive analysis of microbubble technology, including its manufacturing techniques and use in cancer medication delivery.